Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 481: Which drug is not used in the management of Prinzmetal angina?

A. Propranolol (Correct Answer)
B. Propranolol
C. Nitrites
D. Isosorbide dinitrate

Explanation: **Explanation:** **Prinzmetal Angina (Variant Angina)** is caused by transient coronary artery vasospasm rather than fixed atherosclerotic obstruction. The management focuses on inducing vasodilation and preventing spasm. **Why Propranolol is the correct answer (Contraindicated):** Propranolol is a non-selective beta-blocker. In Prinzmetal angina, blocking $\beta_2$ receptors (which mediate vasodilation) leaves the $\alpha_1$ receptors (which mediate vasoconstriction) unopposed. This "unopposed alpha-adrenergic stimulation" can exacerbate coronary artery vasospasm, worsening the ischemia. Therefore, beta-blockers are strictly contraindicated in this condition. **Analysis of Incorrect Options:** * **Nitrites (Nitroglycerin):** These are potent venodilators and coronary vasodilators. They provide rapid relief by directly relaxing the smooth muscles of the coronary arteries, reversing the spasm. * **Isosorbide Dinitrate:** This is a long-acting nitrate used for the prophylaxis of anginal attacks. Like other nitrates, it promotes nitric oxide release, leading to vasodilation. * **Calcium Channel Blockers (CCBs):** Though not listed as an option, CCBs (like Amlodipine or Diltiazem) are the **drugs of choice** for Prinzmetal angina as they effectively prevent coronary artery spasm. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Calcium Channel Blockers (CCBs). * **Contraindicated:** Non-selective Beta-blockers (Propranolol). * **ECG Finding:** Transient ST-segment elevation (not depression) during the attack, which returns to normal once the pain subsides. * **Trigger:** Often occurs at rest, typically in the early morning hours, and is frequently associated with smoking.

Question 482: Which of the following drugs has been shown to prolong life in patients with chronic congestive heart failure but has a negative inotropic effect on cardiac contractility?

A. Carvedilol (Correct Answer)
B. Digoxin
C. Enalapril
D. Furosemide

Explanation: **Explanation:** The correct answer is **Carvedilol**. **1. Why Carvedilol is correct:** Carvedilol is a non-selective beta-blocker with alpha-1 blocking properties. Traditionally, beta-blockers were contraindicated in heart failure due to their **negative inotropic effect** (reduction in force of contraction). However, in chronic congestive heart failure (CHF), there is chronic overactivation of the sympathetic nervous system, which leads to cardiac remodeling and apoptosis. By blocking these effects, Carvedilol reduces cardiac workload, prevents remodeling, and has been proven in trials (like COPERNICUS) to **prolong life and reduce mortality**. **2. Why other options are incorrect:** * **Digoxin:** This is a positive inotrope. While it improves symptoms and reduces hospitalization rates in CHF, it has **no proven mortality benefit** (it does not prolong life). * **Enalapril:** This is an ACE inhibitor. While it is a first-line drug that **prolongs life** in CHF, it does not have a negative inotropic effect; it works primarily by reducing preload and afterload through vasodilation. * **Furosemide:** This is a loop diuretic used for symptomatic relief of edema and congestion. It does not have a negative inotropic effect and has **no mortality benefit** in chronic CHF. **High-Yield Clinical Pearls for NEET-PG:** * **Mortality Benefit Drugs in CHF:** ACE inhibitors/ARBs, Beta-blockers (Carvedilol, Metoprolol succinate, Bisoprolol), Spironolactone (MRAs), and SGLT2 inhibitors. * **Beta-blocker Initiation:** Always start at very low doses ("Start low, go slow") only when the patient is **hemodynamically stable** (euvolemic), never during an acute decompensated phase. * **Carvedilol's unique property:** It also possesses antioxidant and anti-proliferative properties, further aiding in reversing cardiac remodeling.

Question 483: What is the mechanism of action of fibrates?

A. Inhibition of HMG-CoA reductase
B. Inhibition of HMG-CoA synthase
C. Inhibition of cholesterol absorption
D. Inhibition of release of triglycerides and LDL (Correct Answer)

Explanation: ### Explanation **Mechanism of Action of Fibrates** Fibrates (e.g., Fenofibrate, Gemfibrozil) primarily act as agonists of the **Peroxisome Proliferator-Activated Receptor-alpha (PPAR-α)**, a nuclear receptor found mainly in the liver and muscles. 1. **Why Option D is Correct:** Activation of PPAR-α leads to increased expression of **Lipoprotein Lipase (LPL)**, which enhances the catabolism of triglyceride-rich particles (VLDL). It also decreases the hepatic synthesis and release of VLDL (the precursor to LDL) and reduces the expression of ApoC-III (an LPL inhibitor). Consequently, there is a significant **reduction in plasma triglycerides** and a modest reduction in LDL. Additionally, fibrates increase the synthesis of ApoA-I and ApoA-II, which **raises HDL levels**. **Analysis of Incorrect Options:** * **Option A & B:** Inhibition of **HMG-CoA reductase** is the mechanism of **Statins** (the rate-limiting step in cholesterol synthesis). HMG-CoA synthase is an earlier enzyme in the pathway and is not a primary target for current lipid-lowering drugs. * **Option C:** Inhibition of cholesterol absorption at the brush border of the small intestine is the mechanism of **Ezetimibe**. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Fibrates are the first-line treatment for **Severe Hypertriglyceridemia** (TG >500 mg/dL) to prevent acute pancreatitis. * **Side Effects:** Myopathy and gallstones (cholelithiasis) due to increased biliary cholesterol excretion. * **Drug Interaction:** Combining fibrates (especially Gemfibrozil) with Statins significantly increases the risk of **Rhabdomyolysis** because they compete for the same glucuronidation pathway (UGT1A1/3).

Question 484: Which of the following statements is not true regarding the use of clonidine in the treatment of hypertension?

A. Reduces central sympathetic outflow.
B. Increases LDL-cholesterol with prolonged use. (Correct Answer)
C. Sedation and xerostomia are common side effects.
D. Can be combined with vasodilators.

Explanation: Clonidine is a centrally acting antihypertensive agent. The correct answer is **B** because clonidine is **metabolically neutral**; it does not adversely affect lipid profiles (LDL, HDL, or triglycerides) or glucose metabolism, making it safe for patients with dyslipidemia or diabetes. ### **Explanation of Options:** * **Option A (True):** Clonidine is a selective **$\alpha_2$-adrenergic agonist** in the nucleus tractus solitarius of the medulla. Stimulation of these receptors inhibits the vasomotor center, leading to a reduction in central sympathetic outflow and a decrease in blood pressure. * **Option B (False/Correct Answer):** As stated, clonidine has no significant effect on plasma lipids. This is a high-yield distinction from older diuretics or non-selective beta-blockers which may alter lipid profiles. * **Option C (True):** Due to its central action and inhibition of salivary secretions, **sedation** and **xerostomia** (dry mouth) are the most frequently reported side effects, occurring in up to 50% of patients. * **Option D (True):** Clonidine can be combined with vasodilators (like hydralazine). Vasodilators often cause reflex tachycardia; clonidine helps counteract this by reducing sympathetic tone. ### **High-Yield Clinical Pearls for NEET-PG:** * **Rebound Hypertension:** Sudden withdrawal of clonidine can cause a hypertensive crisis due to a massive surge in catecholamines. It must be tapered slowly. * **Treatment of Rebound HTN:** Managed with a combination of $\alpha$ and $\beta$ blockers (e.g., Phentolamine + Propranolol) or Labetalol. * **Other Uses:** Clonidine is also used in opioid withdrawal, ADHD, Tourette syndrome, and hot flashes.

Question 485: ACE inhibitors are contraindicated in all of the following conditions except:

A. Pregnancy
B. Diabetes (Correct Answer)
C. Bilateral renal artery stenosis
D. Renal failure

Explanation: **Explanation:** ACE inhibitors (ACEIs) are the **drugs of choice** for patients with **Diabetes Mellitus**, especially those with diabetic nephropathy. This is because they exert a Reno-protective effect by dilating the efferent arteriole, thereby reducing intraglomerular pressure and decreasing proteinuria. **Why the other options are contraindicated:** * **Pregnancy (Option A):** ACEIs are absolute contraindications (Teratogenic). They interfere with fetal kidney development, leading to oligohydramnios, fetal renal failure, and skull hypoplasia. * **Bilateral Renal Artery Stenosis (Option C):** In this condition, glomerular filtration rate (GFR) is maintained by Angiotensin II-mediated vasoconstriction of the efferent arteriole. ACEIs block this mechanism, leading to a precipitous drop in GFR and acute renal failure. * **Renal Failure (Option D):** While ACEIs are used in early chronic kidney disease, they are generally contraindicated in advanced renal failure or acute kidney injury, particularly if serum creatinine is >3 mg/dL or if there is pre-existing hyperkalemia, as ACEIs further increase potassium levels. **NEET-PG High-Yield Pearls:** 1. **Side Effects:** The most common side effect is a **dry cough** (due to increased Bradykinin); the most serious is **Angioedema**. 2. **Drug of Choice:** ACEIs are first-line for Hypertension in patients with Diabetes, Heart Failure, and post-Myocardial Infarction. 3. **Monitoring:** Always monitor Serum Potassium and Creatinine levels within 1-2 weeks of starting therapy.

Question 486: Beta-blockers mask all the symptoms of hypoglycemia except which one?

A. Sweating (Correct Answer)
B. Increased heart rate
C. Hypertension
D. None of the above

Explanation: **Explanation:** Hypoglycemia triggers a massive sympathetic (autonomic) surge, leading to symptoms such as tachycardia, palpitations, tremors, and anxiety. These symptoms are primarily mediated by **$\beta_1$ and $\beta_2$ adrenergic receptors**. **1. Why Sweating is the Correct Answer:** Sweating (diaphoresis) is the only sympathetic symptom of hypoglycemia that remains unmasked by beta-blockers. This is because the postganglionic sympathetic fibers innervating sweat glands are **cholinergic** (they release Acetylcholine acting on Muscarinic receptors), not adrenergic. Since beta-blockers only antagonize adrenergic receptors, they have no effect on the cholinergic pathway responsible for sweating. **2. Why the Other Options are Incorrect:** * **Increased heart rate (Tachycardia):** This is mediated by $\beta_1$ receptors in the heart. Beta-blockers effectively block these receptors, preventing the compensatory rise in heart rate during hypoglycemia. * **Hypertension/Tremors/Palpitations:** These are also mediated by adrenergic receptors ($\beta_1$ and $\beta_2$). Beta-blockers suppress these "warning signs," which can lead to "hypoglycemia unawareness"—a dangerous clinical state. **Clinical Pearls for NEET-PG:** * **The "Masking" Effect:** Beta-blockers are used with extreme caution in diabetic patients because they hide the early warning signs of hypoglycemia, except for sweating. * **The "Pressor" Effect:** In hypoglycemia, there is a massive release of Epinephrine. If a non-selective beta-blocker (like Propranolol) is used, $\beta_2$-mediated vasodilation is blocked, leaving **$\alpha_1$-mediated vasoconstriction unopposed**. This can lead to a paradoxical, severe hypertensive crisis. * **Metabolic Impact:** Beta-blockers also inhibit glycogenolysis and gluconeogenesis (mediated by $\beta_2$ receptors), which can delay recovery from a hypoglycemic episode.

Question 487: The drug Vorapaxar acts by primarily inhibiting platelet aggregation caused by which of the following substances?

A. Thromboxane
B. ADP
C. Thrombin (Correct Answer)
D. Prostacyclin

Explanation: **Explanation:** **Vorapaxar** is a novel antiplatelet agent that acts as a competitive, selective, and reversible antagonist of the **Protease-Activated Receptor-1 (PAR-1)**. PAR-1 is the primary receptor for **Thrombin** on human platelets. Thrombin is the most potent activator of platelets; by blocking this receptor, Vorapaxar inhibits thrombin-induced platelet aggregation without interfering with thrombin’s ability to convert fibrinogen to fibrin (clot formation). **Analysis of Incorrect Options:** * **A. Thromboxane:** Thromboxane A2 (TXA2) synthesis is inhibited by **Aspirin** (via COX-1 inhibition). * **B. ADP:** Adenosine Diphosphate (ADP) receptors (P2Y12) are the targets of drugs like **Clopidogrel, Prasugrel, and Ticagrelor**. * **D. Prostacyclin:** This is a potent endogenous inhibitor of platelet aggregation (anti-thrombotic). Inhibiting it would promote, rather than prevent, aggregation. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Vorapaxar is used for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). * **Pharmacokinetics:** It has a very long half-life (approx. 8 days), making its effects essentially irreversible in clinical practice. * **Contraindication:** It is strictly contraindicated in patients with a history of **Stroke, TIA, or Intracranial Hemorrhage** due to a significantly increased risk of bleeding. * **Metabolism:** It is metabolized by **CYP3A4**; thus, co-administration with strong CYP3A4 inhibitors or inducers should be avoided.

Question 488: Which of the following is NOT a cardioselective beta-blocker?

A. Acebutolol
B. Atenolol
C. Pindolol (Correct Answer)
D. Metoprolol

Explanation: ### Explanation The correct answer is **Pindolol**. Beta-blockers are classified based on their receptor selectivity. **Cardioselective beta-blockers** (also known as second-generation beta-blockers) primarily inhibit $\beta_1$-receptors located in the heart, minimizing the bronchoconstriction associated with $\beta_2$-blockade [1]. **1. Why Pindolol is the correct answer:** Pindolol is a **non-selective beta-blocker**, meaning it blocks both $\beta_1$ and $\beta_2$ receptors. Furthermore, it possesses significant **Intrinsic Sympathomimetic Activity (ISA)**, acting as a partial agonist [2]. This means it causes less bradycardia at rest compared to pure antagonists, making it a unique choice for patients who need beta-blockade but have borderline bradycardia. **2. Why the other options are incorrect:** * **Acebutolol:** A cardioselective ($\beta_1$) blocker. Notably, it also possesses ISA and membrane-stabilizing activity. * **Atenolol:** A classic cardioselective ($\beta_1$) blocker. It is hydrophilic and has a low lipid solubility, resulting in minimal CNS side effects [2]. * **Metoprolol:** A prototype cardioselective ($\beta_1$) blocker. It is widely used in the management of post-MI patients and heart failure [2]. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for Cardioselective ($\beta_1$) Blockers:** *"New Beta Blockers Are Exclusive to My Heart"* (**N**ebivolol, **B**isoprolol, **B**etaxolol, **A**tenolol, **A**cebutolol, **E**smolol, **M**etoprolol). * **Esmolol:** The shortest-acting beta-blocker (half-life ~9 minutes), administered IV for hypertensive emergencies or supraventricular tachycardia. * **Nebivolol:** The most highly selective $\beta_1$ blocker which also promotes vasodilation via Nitric Oxide (NO) release. * **Non-selective blockers with $\alpha_1$ blocking activity:** Labetalol and Carvedilol (Third-generation).

Question 489: Which of the following drugs is contraindicated in hypertrophic obstructive cardiomyopathy (HOCM)?

A. Verapamil
B. Propranolol
C. Digoxin (Correct Answer)
D. None of the above

Explanation: **Explanation:** In **Hypertrophic Obstructive Cardiomyopathy (HOCM)**, the primary pathology is a dynamic left ventricular outflow tract (LVOT) obstruction caused by asymmetrical septal hypertrophy and systolic anterior motion (SAM) of the mitral valve. **Why Digoxin is contraindicated:** Digoxin is a positive inotropic agent. By increasing the force of myocardial contraction, it narrows the outflow tract further during systole, thereby worsening the obstruction. Additionally, any drug that increases heart rate or decreases ventricular filling (preload) exacerbates the gradient in HOCM. Therefore, **Digoxin (and other inotropes like Dobutamine) are strictly contraindicated.** **Analysis of other options:** * **Verapamil (Option A):** This is a drug of choice in HOCM. As a non-dihydropyridine calcium channel blocker, it provides negative inotropy and improves diastolic filling (lusitropy), which helps reduce the outflow gradient. * **Propranolol (Option B):** Beta-blockers are the first-line treatment for symptomatic HOCM. They decrease heart rate (increasing diastolic filling time) and reduce the force of contraction, which lessens the LVOT obstruction. **High-Yield Clinical Pearls for NEET-PG:** * **Avoid the "3 Ds" in HOCM:** **D**igoxin, **D**iuretics (reduce preload), and **D**ilators (Nitrates/ACE inhibitors reduce afterload/preload), as all three worsen the obstruction. * **Management Goal:** Increase preload and decrease contractility to "keep the ventricle full and quiet." * **Drug of Choice:** Beta-blockers (e.g., Propranolol) or Verapamil. * **Auscultation:** The murmur of HOCM *increases* with Valsalva maneuver or standing (decreased preload) and *decreases* with squatting (increased preload).

Question 490: When treating hypertension chronically, orthostatic hypotension is maximum with which of the following medications?

A. Clonidine
B. Guanethidine (Correct Answer)
C. Prazosin
D. Propranolol

Explanation: Guanethidine is the correct answer because it is a potent adrenergic neuron blocker. It works by inhibiting the release of norepinephrine from postganglionic sympathetic nerve endings and depleting catecholamine stores [1]. By profoundly blocking sympathetic outflow, it prevents the compensatory vasoconstriction that normally occurs upon standing. This leads to a severe drop in blood pressure, making orthostatic (postural) hypotension its most characteristic and dose-limiting side effect [1], [3]. **Analysis of Incorrect Options:** * **Clonidine (A):** An alpha-2 agonist that acts centrally to reduce sympathetic outflow. While it causes sedation and dry mouth, it rarely causes significant orthostatic hypotension because it does not completely paralyze peripheral sympathetic reflexes [2]. * **Prazosin (C):** A selective alpha-1 blocker. It is notorious for the **"first-dose phenomenon"** (severe syncope after the initial dose), but with chronic use, the risk of orthostatic hypotension is significantly less than that of Guanethidine. * **Propranolol (D):** A non-selective beta-blocker. It reduces blood pressure primarily by decreasing cardiac output and renin release. It does not interfere with alpha-mediated vasoconstriction; therefore, orthostatic hypotension is not a typical side effect. **High-Yield Clinical Pearls for NEET-PG:** * **Guanethidine** is rarely used today due to its side effect profile, which includes **explosive diarrhea** and **retrograde ejaculation**. * **Tricyclic Antidepressants (TCAs)** can block the uptake of Guanethidine into the neuron, thereby reversing its antihypertensive effect [1]. * **Rule of Thumb:** Drugs that interfere with peripheral sympathetic transmission (Guanethidine, Alpha-blockers) cause more orthostatic hypotension than those acting centrally (Clonidine) or on the heart (Beta-blockers).

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free